TG4050
TG4050 is an individualized therapeutic vaccine
A particularly innovative immunotherapy, TG4050 is the lead myvac ® candidate.
- Bespoke therapeutic vaccine
- Phase I
- Ovarian cancer; HPV-negative head & neck cancers
- myvac® platform
- Mechanism of action

A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in each patient’s tumor.
Collaboration agreements
Transgene has signed a strategic collaboration agreement with NEC for the development of TG4050, the first candidate derived from the myvac® platform. This personalized immunotherapy is developed for each patient, on the basis of mutations identified through sequencing of tumor tissue, prioritized using NEC’s Neoantigen Prediction System and delivered using Transgene’s myvac® technological platform which allows development and manufacturing.
- April 13, 2026Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
- April 2, 2026Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
- January 9, 2026Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
Discover myvac®
Clinical trials
| Indication | Phase | |
|---|---|---|
| Ovarian cancer – after first-line surgery and chemotherapy | Phase I | More information |
| HPV-negative head and neck cancers – after surgery and adjuvant therapy | Phase I | More information |
- A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial
C. Ottensmeier, et al.
Article available on Nature Communications website – Download the Article - TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment
K. Bidet-Huang
World Vaccine Congress 2026 – Download the Oral Presentation - Viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: immunogenicity and efficacy from a randomized Phase I trial
C. Ottensmeier, et al.
medRxiv Preprint available on medRxiv website – Download the Article